골다공증 및 골감소증 치료제의 치료효과 비교연구

Abstract

Purpose: The aim of this study was to compare retrospectively the efficacy of anti-osteoporotic agents (RAL-Raloxifene60 mg, ALD-weekly alendronate 70 mg, RSD-weekly risedronate 35 mg, AVD3-weekly alendronate 70 mg/vitaminD3 2800IU, IBD-quarterly IV ibandronate 3 mg/3 ml, ZLD-yearly IV zoledronate 5 mg/100 ml) in postmenopausalpatients with osteoporosis or osteopenia. Method: This study retrospectively reviewed medical record and compared thelumbar spine BMD percentage changes of each medicine group one year later from the baseline. 209 patients (27, 50,60, 30, 35, and 7 patients in RAL, ALD, RSD, AVD3, IBD, and ZLD groups, respectively) are within the inclusion criteriafor the study. Results: From baseline to month 12, lumbar spine BMD increased significantly larger with bisphosphonategroups, compared to SERM (p < 0.05). In all bisphosphonate groups, the lumbar spine BMD were increasedsignificantly from baseline. Of the bisphosphonates, the changes from baseline in BMD of IV bisphosphonates weremore larger than those of oral bisphosphonates, and yearly, quarterly bisphosphonates yielded significantly greater BMDgains, compared with weekly bisphosphonate groups (p < 0.05). In addition, patients receiving 70 mg weekly alendronate+vitamin D3 had greater gains in BMD than alendronate Single preparation (p < 0.05). Conclusion: Bisphosphonatesyielded significantly greater BMD gains than SERM. Of the bisphosphonates, the changes from baseline in BMDof yearly, quarterly IV bisphosphonates yielded significantly greater BMD gains, compared with weekly oral bisphosphonategroups. In addition, vitamin D3 plays an significant role in BMD gains.